We read with great interest the article ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al.1 This study showed that glucocorticoid exposure of ≥10 mg/day was associated with higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with COVID-19 with rheumatic disease. Like this report, studies on the relationship between COVID-19 and rheumatic diseases are needed. Although several cases of vasculitis, such as large vessel vasculitis (LVV) and Kawasaki disease, have been reported among patients with COVID-19,2 3 there are no recorded cases of adult LVV developing after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We report a case of this development.
A 25-year-old was infected twice with the coronavirus earlier this year, scientists in Nevada have confirmed. It is the first confirmed case of so-called reinfection with the virus in the U.S. and the fifth confirmed reinfection case worldwide.
A number of investigational agents and drugs that are approved for other indications are currently being studied in clinical trials for the treatment of COVID-19 and associated complications. Data from randomized controlled trials, prospective and retrospective observational cohorts, and case series studies are rapidly emerging. The COVID-19 Treatment Guidelines Panel (the Panel) continues to review the most recent clinical data to provide up-to-date treatment recommendations to clinicians who are caring for patients with COVID-19. In this section, the Panel recommends strategies for managing patients with different severities of disease. A comprehensive summary of clinical data for drugs that are being investigated can be found in the Antiviral Therapy, Immune-Based Therapy, and Adjunctive Therapy sections of these Guidelines.
Experts noted monoclonal antibodies have yet to show an impact on clinical outcomes
Official Reporting for October 12, 2020
World Health Organization
Cumulative Cases: 37,423,660
Cumulative Deaths: 1,074,817
Confirmed Cases: 37 568 843
Deaths: 1 077 508
Confirmed Cases: 37,722,044
Total cases: 7,740,934
Total deaths: 214,108
Wisconsin: Wisconsin Judge Upholds Mask Mandate As Coronavirus Cases Surge – Forbes
Washington D.C.: How The Coronavirus Has Affected Individual Members Of Congress – NPR
Washingron D.C.: White House hosted Covid ‘superspreader’ event, says Dr Fauci – BBC
Utah: Hospital officials warn state in ‘precarious’ situation with record COVID-19 hospitalizations – Deseret News
Montana: Struggling With A Coronavirus Surge – NPR
New York: Covid-19 Cases Keep Rising in Some New York Hot Spots – Wall Street Journal
Iran: Iran records its highest daily death toll from coronavirus – Los Angeles Times
China: Testing 9 Million People For Covid-19 This Week As New Outbreak Emerges – Forbes
China: China Ends Virus-Free Streak as Cluster in Port City Emerges – Bloomberg
India: India’s coronavirus infections cross 7 million ahead of festivals – Reuters
Europe tightens restrictions as COVID-19 cases rise – CBS News
Germany: Kaiserslautern area raised to second-highest health alert level as coronavirus cases surge in Germany – Stars and Stripes
Science and Tech
COVID-19 causing virus lasts for 10 days longer than Influenza on some surfaces Lower temps, glass, stainless steel and paper banknotes give virus longer life.
In another era, what happened Wednesday might have been viewed simply as good news. Two companies, Regeneron Pharmaceuticals and Eli Lilly, have independently developed therapeutic drugs, called monoclonal antibodies, that in preliminary testing appear to reduce symptoms for coronavirus patients. They applied for emergency use authorization from the Food and Drug Administration.
In the face of nearly seven million infections and 200,000 deaths, many Americans refuse to wear masks because they don’t feel the coronavirus is real. Even some of those who believe the virus exists are not concerned about getting sick.
Do-it-yourself scientist says human biology too ‘messy’ to get a clear reading in a small trial.
Two trials for more than 6,000 people are starting in the next few weeks looking at prevention, with plans for a further 4,000 adults to test the antibody medicine as a treatment, Astra said in a statement. The drug will be assessed for its ability to avoid infections for as much as a year in some people and as a pre-emptive medicine once patients have been exposed to the virus in others.
Psychological and Sociological Impact
The coronavirus pandemic has created the perfect storm for couples contemplating divorce in the D.C. area. Making a marriage work is challenging enough when things are going well. But when you add COVID-19 into the mix, it becomes much harder. For many couples, it was too much.
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies – Nature
Overall decrease of SARS-CoV-2 viral load and reduction of clinical burden: the experience of a Northern Italy hospital – Clinical Microbiology and Infection
Advancement in biosensors for inflammatory biomarkers of SARS-CoV-2 during 2019–2020 – Bioscensors and Bioelectroics
Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019 – PLoS One
Is recurrence possible in coronavirus disease 2019 (COVID-19)? Case series and systematic review of literature – European Journal of Clinical Microbiology & Infectious Diseases
An aberrant STAT pathway is central to COVID-19 – Nature / cell death & differentiation
Genomic evidence for reinfection with SARS-CoV-2: a case study – The Lancet
Misinformation, Disinformation, and Conspiracy Theories
- THE VIRUS WAS ENGINEERED IN A LABORATORY IN CHINA.
Because the pathogen first emerged in Wuhan, China, President Donald Trump and others have claimed, without evidence, that it started in a lab there, and some conspiracy theorists believe it was engineered as a bioweapon.